5 Best-performing Canadian Pharma Stocks in 2026

1. Medexus Pharmaceuticals (TSX:MDP)

Year-on-year gain: 74.34 percent
Market cap: C$125 million
Share price: C$3.94

Medexus Pharmaceuticals is a specialty pharmaceutical company that acquires, develops and commercializes niche and rare disease drugs in North America. The company has honed in on hematology, oncology, rheumatology, autoimmune disease, allergies and dermatology. It focuses on bringing in late‑stage or already marketed products via licensing/partnerships and then handling regulatory approval and commercialization in Canada and the US.

GRAFAPEX, one of the most important branded products in the company's portfolio, is a conditioning regimen used with fludarabine before allogeneic hematopoietic stem cell transplant in patients with AML/MDS.

In Medexus' results for its third fiscal quarter of 2026, management points to continued strength from GRAFAPEX as a key driver of the company’s year‑to‑date performance.

2. BioSyent (TSXV:RX)

Year-on-year gain: 46.63 percent
Market cap: C$173.84 million
Share price: C$15.25

BioSyent is a specialty pharmaceutical company focused on in-licensing or acquiring established, high-margin healthcare products for the Canadian and international markets. Its growth is anchored by brands in iron health and women's wellness. Its flagship brand, FeraMAX, has been Canada's leading iron supplement for over a decade.

The company's 2024 acquisition of Tibelia, a treatment for menopausal symptoms, has been a major growth driver, with a 302 percent year-on-year rise in international pharma sales in 2025.

In March, the company granted 44,222 restricted share units to directors, officers, management and employees under its three year restricted share unit plan, reinforcing long‑term, performance‑aligned compensation.

3. Knight Therapeutics (TSX:GUD)

Year-on-year gain: 29.95 percent
Market cap: C$749.97 million
Share price: C$7.55

Knight Therapeutics is a specialty pharmaceutical company headquartered in Montreal, Québec.

It operates on an acquisition and in-licensing model, obtaining the rights to innovative medicines from global pharmaceutical companies and commercializing them across Canada and Latin America.

The company was originally founded by the former leaders of Paladin Labs, which was acquired by Endo International in 2014. In June 2025, Knight bought the Paladin business back from Endo for C$107 million in cash, adding over 40 products to its Canadian roster. These additions helped drive 21 percent year-on-year revenue growth in 2025, with Knight reporting C$450.09 million for the period.

Also driving that growth was a mid-2025 deal with Sumitomo Pharma America.

4. Satellos Bioscience (TSXV:MSCL)

Year-on-year gain: 14.27 percent
Market cap: C$179.36 million
Share price: C$9.05

Satellos Bioscience is a Canadian pharmaceutical company expanding treatment options for muscle disorders.

The company is focused specifically on Duchenne muscular dystrophy, developing therapies that target the specific biological pathways involved in regenerating and repairing muscle tissue. Its lead candidate, SAT-3247, targets a protein called AAK1, which regulates the activity of stem cells that activate and differentiate new muscle fibers.

In the fourth quarter of 2025, Satellos administered the first dose to a patient in its 11 month open-label follow-up study for adults who completed its initial Phase 1b trial. The study seeks to demonstrate the lasting impact of the significant functional improvements observed earlier in the year.

In December 2025, the company received investigational new drug clearance from the US Food and Drug Administration and several other global regulators to initiate BASECAMP, a global Phase 2 randomized, placebo-controlled study to evaluate SAT-3247 in pediatric patients.

On February 12, Satellos reported that the first participant had been dosed.

In its latest quarterly report, released on March 27, management said it expects that cash, plus a US$57.2 million February equity raise, will fund operations through 2027.

5. HLS Therapeutics (TSX:HLS)

Year-on-year gain: 10.71 percent
Market cap: C$137.60 million
Share price: C$4.55

HLS Therapeutics focuses on drugs for cardiovascular and central nervous system problems, often through partnerships. It specializes in acquiring and commercializing pharmaceuticals that address unmet needs, including Vascepa to reduce cardiovascular risk and Clozaril for treatment-resistant schizophrenia. Additionally, the company generates revenue from a diversified portfolio of royalty interests on various products marketed by third parties.

Health Canada's November 2025 approval of LDL-cholesterol-lowering treatment Nilemdo represents the most significant catalyst for the company since the launch of Vascepa; HLS believes the milestone positions it as a dominant leader in the Canadian cardiovascular market. Nilemdo had its commercial launch on March 5.

The company reported essentially flat 2025 revenue at US$55.5 million, but grew adjusted EBITDA 18 percent to US$19.6 million and more than doubled operating cashflow